FDA Orphan Drug Designation and Fast Track Designation for rezafungin
ADC评论
September 22, 2022
On September 20, Cidara/Melinta Therapeutics jointly announced that the FDA has accepted the New Drug Application (NDA) for rezafungin (rezafungin) for the treatment of candidemia
